Kwality Pharmaceuticals has delivered exceptional returns to investors, hitting a 52-week high of ₹3,725.45 on August 17, 2026, while maintaining a 52-week low of ₹828.80 recorded on November 11, 2025. The stock has generated remarkable returns of 238.9% over one year, making it a multibagger and one of the strongest performers in its pharmaceutical segment. The latest momentum was driven by robust Q4 FY26 results that showed total revenue of ₹157.11 crore, growing 35.82% year-on-year from ₹115.68 crore in Q4 FY25. Net income surged 74.62% to ₹25.30 crore compared to ₹14.49 crore in the previous year, with diluted normalized EPS increasing 74.19% to ₹24.40 from ₹14.01. According to reports from The Financial Express, this performance reflects strong investor confidence in the company's growth trajectory and registration pipeline.
The company has demonstrated robust financial performance with revenue growing from ₹251 crore in FY23 to ₹503 crore in FY26, representing 100% growth over three years. More significantly, profit after tax has grown from ₹19 crore to ₹67 crore across the same period, indicating substantial operating leverage benefits. As reported by The Financial Express, Q1 FY27 continued this momentum with revenue of ₹162 crore growing 45.7% year-on-year from ₹111 crore in Q1 FY26. The operating profit margin expanded to 25% from 22%, while PAT increased approximately 115% to ₹26 crore compared to ₹12 crore in the previous year. The strong Q4 performance further validates this growth trajectory with operating income of ₹33.50 crore, growing 61.03% year-on-year from ₹20.80 crore in Q4 FY25.
Kwality operates through a 90% out-licensing model across 70+ countries, with approximately 10% revenue from CDMO work. The company has filed 700+ regulatory dossiers and maintains six manufacturing units with four of five operational units being EU-GMP approved. According to The Financial Express, management indicated that each successful registration can potentially contribute ₹1.5-2 million in annual revenue, with current expectations of 2-3 registrations per quarter translating to incremental revenue, targeting 6-7 registrations per quarter from Q2 FY27. The company maintains a target portfolio of 200-250 products across 70-80 countries.
Management has raised its FY27 revenue guidance to over ₹700 crore from the earlier ₹650 crore target, while retaining EBITDA margin guidance at 27-28% and PAT margin guidance of more than 15.5%. For FY29, the company has guided ₹1,000 crore revenue based primarily on existing businesses and BE programme, with potential contributions from hormone facility and biologics programmes. As reported by The Financial Express, the total capex programme supporting this trajectory totals approximately ₹185-195 crore, including ₹65 crore for the hormone plant, ₹50 crore for oncology expansion, ₹25-30 crore for BE studies, and ₹10-15 crore for biosimilar R&D.
The stock currently trades at a trailing P/E of 42.6x, compared to an industry P/E of 34.1x and three-year median P/E of 23.4x. According to The Financial Express, the Return on Capital Employed (ROCE) of 24.1% and 3-year average ROCE of 19.5% reflect improving capital efficiency as the business scales. The company's Free Cash Flow stands at negative ₹28.6 crore, highlighting current cash-conversion challenges with extended collection cycles in export markets. Management has indicated that the current capex programme is being funded primarily through internal accruals, with a ₹15-20 crore credit line available if required.
